Monday, September 03, 2007

Breast cancer vaccine looks safe, study shows

A therapeutic vaccine designed for breast cancer appears to be safe in women with advanced disease and shows signs of actually slowing down tumor growth, U.S. researchers reported on Friday. Dendreon Corporation, maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called her2/neu-positive breast cancer, which affects between 20 percent and 30 percent of breast cancer patients. Like Provenge, Neuvenge is made using immune cells from the cancer patient, so it is a tailor-made vaccine. --Click the title of this post to read the full article from its source--

Labels: , , , ,

Sunday, September 02, 2007

Dendreon breast cancer drug Neuvenge effective in trial

Dendreon Corp., the developer of a treatment to stimulate the immune system against prostate cancer, said a small study suggests the same technique may help women with breast cancer.
A clinical trial of Neuvenge showed that four of 18 patients taking the treatment, or 22 percent, had their tumors shrink or stabilize, according to results published in the Aug. 20 issue of the Journal of Clinical Oncology. The Seattle-based company, which has no marketed products, lost almost $1 billion of its market value May 9, when its leading drug candidate, Provenge, was delayed by a request from U.S. regulators for more proof that it works. Dendreon presented early results for Neuvenge, its only other drug in human testing, at a scientific meeting in March 2004. The company hasn't invested since in any large clinical trials needed for approval. --Click the title of this post to read the full article from its source--

Labels: , , , ,

/* WebRing Code */